Asmaa A. Hegazy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Asmaa A. Hegazy has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Aboubakr H. Abdelmonsef
Chemistry Department, Faculty of Science, Qena University, Qena 83523, Egypt
1 shared publication - Ahmed S. Osman
Department of Biochemistry, Faculty of Veterinary Medicine, Sohag University, Sohag 82524, Egypt
1 shared publication - Amany Mohamed Hamed
Chemistry Department, Faculty of Science, Sohag University, Sohag 82524, Egypt
1 shared publication - Elsayed Eldeeb Mehana Hamouda
Department of Pathology, College of Veterinary Medicine, Alexandria University, Alexandria 26571, Egypt
1 shared publication - Lobna A. Ali
Cell Biology and Histochemistry, Zoology Department, Faculty of Science, Qena University, Qena 83523, Egypt
1 shared publication - Marwan Elsayed Eldeeb Mehana Hamouda
College of Medicine, Alexandria University, Alexandria 26571, Egypt
1 shared publication
Latest Publications
- Open Access
- 14 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8184
Aucubin Ameliorates Alloxan-Induced Diabetic Liver Injury in Association with Modulation of the Nrf2/HO-1 Antioxidant Axis and NF-κB-Associated Inflammatory and Apoptotic Signaling
Diabetes mellitus is associated with progressive hepatic injury driven by oxidative stress, inflammation, and apoptosis. Aucubin, a natural iridoid glycoside, possesses potent antioxidant and anti-inflammatory activities; however, its hepatoprotective mechanisms in diabetic liver injury remain unclear. This study investigated the protective effects of aucubin against alloxan-induced diabetic hepatic injury and the underlying molecular mechanisms. Male albino rats were assigned to five groups: normal control, alloxan-induced diabetic, diabetic treated with metformin (150 mg/kg), and diabetic treated with aucubin (25 or 50 mg/kg) for 28 days. We evaluated body weight, fasting blood glucose, liver function, lipid profile, oxidative stress biomarkers, inflammatory cytokines, and hepatic expression of Nrf2, HO-1, NF-κB p65, Bax, and Bcl-2, along with histopathological and immunohistochemical examinations. Alloxan induced marked hyperglycemia, weight loss, hepatic dysfunction, dyslipidemia, oxidative stress, inflammation, and apoptosis. Aucubin significantly ameliorated these alterations, with the 50 mg/kg dose generally showing greater effects than the 25 mg/kg dose. Aucubin improved liver function, ameliorated dyslipidemia, reduced lipid peroxidation, enhanced antioxidant defenses, increased Nrf2 and HO-1 expression, attenuated NF-κB p65 expression and pro-inflammatory cytokines, favorably modulated the Bax/Bcl-2 balance, preserved hepatic architecture, and increased Ki-67 immunoreactivity, indicating enhanced cellular proliferative activity. These findings indicate that aucubin is associated with improved hepatic antioxidant, inflammatory, apoptotic, and metabolic status in alloxan-induced diabetic rats.
- 14 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8184
Open AccessAucubin Ameliorates Alloxan-Induced Diabetic Liver Injury in Association with Modulation of the Nrf2/HO-1 Antioxidant Axis and NF-κB-Associated Inflammatory and Apoptotic Signaling
Diabetes mellitus is associated with progressive hepatic injury driven by oxidative stress, inflammation, and apoptosis. Aucubin, a natural iridoid glycoside, possesses potent antioxidant and anti-inflammatory activities; however, its hepatoprotective mechanisms in diabetic liver injury remain unclear. This study investigated the protective effects of aucubin against alloxan-induced diabetic hepatic injury and the underlying molecular mechanisms. Male albino rats were assigned to five groups: normal control, alloxan-induced diabetic, diabetic treated with metformin (150 mg/kg), and diabetic treated with aucubin (25 or 50 mg/kg) for 28 days. We evaluated body weight, fasting blood glucose, liver function, lipid profile, oxidative stress biomarkers, inflammatory cytokines, and hepatic expression of Nrf2, HO-1, NF-κB p65, Bax, and Bcl-2, along with histopathological and immunohistochemical examinations. Alloxan induced marked hyperglycemia, weight loss, hepatic dysfunction, dyslipidemia, oxidative stress, inflammation, and apoptosis. Aucubin significantly ameliorated these alterations, with the 50 mg/kg dose generally showing greater effects than the 25 mg/kg dose. Aucubin improved liver function, ameliorated dyslipidemia, reduced lipid peroxidation, enhanced antioxidant defenses, increased Nrf2 and HO-1 expression, attenuated NF-κB p65 expression and pro-inflammatory cytokines, favorably modulated the Bax/Bcl-2 balance, preserved hepatic architecture, and increased Ki-67 immunoreactivity, indicating enhanced cellular proliferative activity. These findings indicate that aucubin is associated with improved hepatic antioxidant, inflammatory, apoptotic, and metabolic status in alloxan-induced diabetic rats.